Nov. 20: PI Resistance Reduces Bevirimat Potency
	Some disturbing news for treatment-experienced patients holding out for Myriad Genetics’ maturation inhibitor bevirimat: According to a study published online November 18 in AIDS, resistance to protease inhibitors (PIs) reduces the effectiveness of bevirimat in up to 45 percent of cases.

	Nov. 19: Accelerated Aging of Blood Vessels Linked With Low CD4s
	People with low CD4 cells might be more likely to have signs of accelerated aging of their blood vessels, according to a study published in the December 1 issue of Clinical Infectious Diseases.

	Nov. 18: Hep C Therapeutic Vaccine Shows Hints of Efficacy
	A hepatitis C virus (HCV) therapeutic vaccine—designed to boost immune control of the virus in people already infected with HCV—has demonstrated that such an approach might work, according to a study presented at the American Association for the Study of Liver Disease (AASLD) Conference in Boston, and reported by aidsmap.

	Nov. 17: Early Treatment, Non-AIDS Disease Management Stressed in New European Guidelines
	Antiretroviral (ARV) therapy is now recommended for certain people living with HIV with CD4 counts between 350 and 500 cells, according to new HIV treatment guidelines released this week by the European AIDS Clinical Society (EACS). The revised recommendations, which hint at similar changes to U.S. HIV treatment guidelines expected this winter, also review the screening, prevention and management of many non-AIDS-related diseases that are more likely to be documented in people living with HIV.

	Nov. 16: Low Vitamin D Levels in Alpine HIV Study
	A new study adds to the evidence that vitamin D deficiency is common in people living with HIV. The new data, from an Italian study reported last week at the 12th European AIDS Conference in Cologne, Germany, and summarized by the National AIDS Treatment Advocacy Project (NATAP), underscore the potential importance of testing for and treating low vitamin D levels to thwart the increased risk of bone deterioration and immune system dysfunction in those infected with the virus.

	Nov. 13: HPV Therapeutic Vaccine Works in an Early Trial
	A therapeutic vaccine designed to help the immune system better control human papillomavirus (HPV) was nearly 50 percent effective in eliminating precancerous genital lesions, according to a study published November 5 in The New England Journal of Medicine. These encouraging data raise hopes for treating other HPV-related cancers, notably of the cervix and anus.